Nail psoriasis and biologics.

Since the advent of biologic therapies for psoriasis, reports of efficacy in nail psoriasis have appeared in the literature and at international conferences with increasing frequency.
This article aims to review the existing literature on the use of biologics in the treatment of nail psoriasis.
An extensive literature review was conducted using OVID Medline. Studies examining the efficacy of biologics in the treatment of nail psoriasis were documented.
A literature review revealed few clinical trials specifically concentrating on nail psoriasis; however, nails have been assessed in larger clinical trials for cutaneous psoriasis. A large, multicenter, phase III, double-blind, placebo-controlled study of infliximab administered as a brief induction regimen at weeks 0, 2, and 6 followed by a single infusion every 8 weeks revealed statistically significant mean percent improvement in the Nail Psoriasis Severity Index (NAPSI) score over placebo at both week 10 (26.8% vs -7.7%, respectively; p < .001) and week 24 (57.2% vs -4.1%, respectively; p < .001). For other biologics, evidence has thus far been largely anecdotal, appearing as either case studies or extracted secondarily from open-label prospective trials in plaque psoriasis or psoriatic arthritis.
Infliximab appears to be the most effective treatment for nail psoriasis to date.
AuthorsKristin Noiles, Ronald Vender
JournalJournal of cutaneous medicine and surgery (J Cutan Med Surg) 2009 Jan-Feb Vol. 13 Issue 1 Pg. 1-5 ISSN: 1203-4754 [Print] Canada
PMID19298765 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Immunoglobulin G
  • Immunologic Factors
  • Receptors, Tumor Necrosis Factor
  • Recombinant Fusion Proteins
  • efalizumab
  • Infliximab
  • alefacept
  • Etanercept
  • Antibodies, Monoclonal (administration & dosage, therapeutic use)
  • Etanercept
  • Humans
  • Immunoglobulin G (administration & dosage, therapeutic use)
  • Immunologic Factors (administration & dosage, therapeutic use)
  • Infliximab
  • Nail Diseases (drug therapy)
  • Psoriasis (drug therapy)
  • Receptors, Tumor Necrosis Factor (administration & dosage, therapeutic use)
  • Recombinant Fusion Proteins (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: